Radiotherapy for patients with stage IV classical Hodgkin lymphoma: a propensity-matched analysis of the surveillance, epidemiology, and end results database

References

• Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol. 2008;5(9):543–556. doi:10.1038/ncponc1186.
   PubMedGoogle Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132. doi:10.3322/caac.21438.
   PubMed Web of Science ®Google Scholar
• Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol. 2003;21(4):607–614. doi:10.1200/JCO.2003.12.086.
   PubMed Web of Science ®Google Scholar
• Yahalom J, Ryu J, Straus DJ, Gaynor JJ, Myers J, Caravelli J, Clarkson BD, Fuks Z. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin’s disease treated with alternating chemotherapy combinations. J Clin Oncol. 1991;9(12):2193–2201. doi:10.1200/JCO.1991.9.12.2193.
   PubMed Web of Science ®Google Scholar
• Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van SE, Grozea PN, Morrison FS, Jr CC, Fisher RI. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med. 1994;120(11):903–912. doi:10.7326/0003-4819-120-11-199406010-00002.
   PubMed Web of Science ®Google Scholar
• Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN, Dinshaw KA. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22(1):62–68. doi:10.1200/JCO.2004.01.021.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010;28(20):3352–3359. doi:10.1200/JCO.2009.26.0323.
   PubMed Web of Science ®Google Scholar
• Diehl V, Loeffler M, Pfreundschuh M, Ruehl U, Hasenclever D, Nisters-Backes H, Sieber M, Smith K, Tesch H, Geilen W, et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin’s disease. German Hodgkins’ Study Group (GHSG). Ann Oncol. 1995;6(9):901–910. doi:10.1093/oxfordjournals.annonc.a059357.
   PubMed Web of Science ®Google Scholar
• Ferme C, Sebban C, Hennequin C, Diviné M, Lederlin P, Gabarre J, Ferrant A, Caillot D, Bordessoule D, Brice P, et al.. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the groupe d’etudes des lymphomes de l’Adulte H89 trial. Blood. 2000;95(7):2246–2252.
   PubMed Web of Science ®Google Scholar
• Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, Maazen RW, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348(24):2396–2406. doi:10.1056/NEJMoa022628.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin study group. J Clin Oncol. 2011;29(32):4234–4242. doi:10.1200/JCO.2010.33.9549.
   PubMed Web of Science ®Google Scholar
• Vargo JA, Gill BS, Balasubramani GK, Beriwal S. Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol. 2015;33(32):3710–3717. doi:10.1200/JCO.2015.61.7654.
   PubMed Web of Science ®Google Scholar
• Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–862. doi:10.1016/j.ijrobp.2013.05.005.
   PubMed Web of Science ®Google Scholar
• Bates JE, Dhakal S, Mazloom A, Casulo C, Constine LS. Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: a propensity matched analysis of the surveillance, epidemiology, and end results database. Radiother Oncol. 2017;124(2):325–330. doi:10.1016/j.radonc.2017.07.016.
   PubMed Web of Science ®Google Scholar
• Master S, Koshy N, Wilkinson B, Rosen L, Mills G, Mansour R, Shi R. Effect of radiation therapy on survival in hodgkin’s lymphoma: a SEER data analysis. Anticancer Res. 2017;37(6):3035–3043. doi:10.21873/anticanres.11658.
   PubMed Web of Science ®Google Scholar
• Son CH, Chiu BC, Koshy M. Patterns of care and survival outcomes examining radiation therapy for advanced Hodgkin lymphoma. Leuk Lymphoma. 2017;58(2):343–347. doi:10.1080/10428194.2016.1193856.
   PubMed Web of Science ®Google Scholar
• Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8(12):1117–1121.
   PubMed Web of Science ®Google Scholar
• Cook RD, Weisberg S. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55. doi:10.1093/biomet/70.1.41.
   Web of Science ®Google Scholar
• Ad V B, Paltiel O, Glatstein E. Radiotherapy for early-stage Hodgkin’s lymphoma: a 21st century perspective and review of multiple randomized clinical trials. Int J Radiat Oncol Biol Phys. 2008;72(5):1472–1479. doi:10.1016/j.ijrobp.2008.08.026.
   PubMed Web of Science ®Google Scholar
• Filippi AR, Franco P, Ciammella P. Role of modern radiation therapy in early stage Hodgkin’s lymphoma: A young radiation oncologists’ perspective. Rep Pract Oncol Radiother. 2012;17(5):246–250. doi:10.1016/j.rpor.2012.05.003.
   PubMedGoogle Scholar
• Shrestha R, Nee J, Durbin EB, Zia M, Ramlal R, Monohan G, Herzig RH, Fleischman R, Hildebrandt G, Saeed H, et al. Chemotherapy and radiation improve survival in early stage classical Hodgkin lymphoma: a statewide cancer registry analysis. Hemato Onco. 2017;35(S2):315–316. doi:10.1002/hon.2439_55.
   Google Scholar
• Aleman BM, Raemaekers JM, Tomisic R, Baaijens MH, Bortolus R, Lybeert M, Maazen R, Girinsky T, Demeestere G, Lugtenburg P, et al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2007;67(1):19–30. doi:10.1016/j.ijrobp.2006.08.041.
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, Jana M, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799. doi:10.1016/S0140-6736(11)61940-5.
   PubMed Web of Science ®Google Scholar
• Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, Leeuwen E, Holowaty EJ, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20(16):3484–3494. doi:10.1200/JCO.2002.09.038.
   PubMed Web of Science ®Google Scholar
• Aleman BM, Belt-Dusebout AW, De Bruin ML, Veer MB, Baaijens MHA, Boer JP, Hart AAM, Klokman WJ, Kuenen MA, Ouwens GM, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–1886. doi:10.1182/blood-2006-07-034405.
   PubMed Web of Science ®Google Scholar
• Koh ES, Tran TH, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, Pintilie M, Xu T, Chung J, Paul N, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2:13. doi:10.1186/1748-717X-2-13.
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Rosenschold PM, Petersen PM, Specht L. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113–2118. doi:10.1093/annonc/mdt156.
   PubMed Web of Science ®Google Scholar
• Koshy M, Rich SE, Mahmood U, Kwok Y. Declining use of radiotherapy in stage I and II Hodgkin’s disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys. 2012;82(2):619–625. doi:10.1016/j.ijrobp.2010.10.069.
   PubMed Web of Science ®Google Scholar
• Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol. 2011;29(32):4227–4233. doi:10.1200/JCO.2010.30.9799.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Flampouri S, Su Z, Morris CG, Latif N, Dang NH, Lynch J, Li Z, Mendenhall NP. Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys. 2012;83(1):260–267. doi:10.1016/j.ijrobp.2011.06.1959.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P. Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease: eastern cooperative oncology group pilot study E1492. J Clin Oncol. 2000;18(5):972–980. doi:10.1200/JCO.2000.18.5.972.
   PubMed Web of Science ®Google Scholar
• Yahalom J. Role of radiation therapy in Hodgkin’s lymphoma. Cancer J. 2009;15(2):155–160. doi:10.1097/PPO.0b013e3181a1437a.
   PubMed Web of Science ®Google Scholar
• Phan J, Mazloom A, Abboud M, Salehpour M, Reed V, Zreik T, Shihadeh F, Fisher C, Wogan C, Dabaja B. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy. Am J Clin Oncol. 2011;34(5):499–505. doi:10.1097/COC.0b013e3181f477a8.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Radford JA, Cullen MH, Sydes, Matthew R, Walewski J, Jack AS, Maclennan KA, Stenning SP, Clawson S, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom lymphoma group LY09 trial (ISRCTN97144519). J Clin Oncol. 2005;23(36):9208–9218. doi:10.1200/JCO.2005.03.2151.
   PubMed Web of Science ®Google Scholar
• Amitai I, Gurion R, Vidal L, Dann EJ, Raanani P, Gafter-Gvili A. PET-adapted therapy for advanced Hodgkin lymphoma - systematic review. Acta Oncol. 2018;57(6):765–772. doi:10.1080/0284186X.2018.1426877.
   PubMed Web of Science ®Google Scholar
• Shariff SZ, Cuerden MS, Jain AK, Garg AX. The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol. 2008;19(5):841–843. doi:10.1681/ASN.2007121354.
   PubMed Web of Science ®Google Scholar